-
PREDICTING OVERALL SURVIVALIN NON-SMALL CELL LUNG CANCER PATIENTSRECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPYUSING A JOINT MODEL INTEGRATING SERIAL GENETIC AND EPIGENETIC BIOMARKERS
Mar 18, 2026, 21:38 PM -
MACHINE LEARNING-BASED PREDICTION OF 10-YEAR CORONARY HEART DISEASE RISK AND COMPARISON WITH THE FRAMINGHAM RISK SCORE
Mar 18, 2026, 21:38 PM -
DETECTING SAFETY SIGNALS OF BILE ACID THERAPEUTICS: A FDA FAERS-BASED PHARMACOVIGILANCE STUDY
Mar 18, 2026, 21:38 PM -
HAVE PFDD MEETINGS MEANINGFULLY INFORMED NDA AND BLA REVIEWS BY THE CENTER FOR DRUG EVALUATION AND RESEARCH? FINDINGS FROM ANALYSIS OF PRODUCTS APPROVED FROM JUNE 2017 TO DECEMBER 2025
Mar 18, 2026, 21:38 PM -
MEDICAID DRUG REBATE AND SAVINGS IMPLICATIONS OF MOST FAVORED NATION PRICING UNDER THE GENEROUS MEDICAID MODEL
Mar 18, 2026, 21:38 PM -
EVIDENCE GENERATION RECOMMENDATIONS TO SUPPORT GLOBAL PHARMACEUTICAL LAUNCHES FOLLOWING MAJOR POLICY CHANGES IN THE US (INFLATION REDUCTION ACT AND MOST FAVORED NATION) AND EU (JOINT CLINICAL ASSESSMENTS)
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS AND ACCESS CONSIDERATIONS FOR GLP-1-BASED THERAPIES IN TYPE 2 DIABETES AND OBESITY: INSIGHTS FROM US PAYER AND HTA PERSPECTIVES
Mar 18, 2026, 21:38 PM -
CO-PAYMENT FOR ALK SUBLINGUAL IMMUNOTHERAPY TABLETS PAID BY PATIENTS ENROLLED IN A PATIENT SUPPORT PROGRAM IN BRITISH COLUMBIA
Mar 18, 2026, 21:38 PM -
DEFINING CURATIVE POTENTIAL IN EARLY-STAGE MELANOMA: WHERE PHYSICIANS AND PAYERS ALIGN AND WHERE THEY DON’T
Mar 18, 2026, 21:38 PM -
US PAYER COST-OF-CARE ANALYSIS FOR DURVALUMAB IN COMBINATION WITH ETOPOSIDE/PLATINUM VS ATEZOLIZUMAB-BASED REGIMENS IN 1L ES-SCLC SETTING
Mar 18, 2026, 21:38 PM -
COST OF HYPERTENSION MANAGEMENT AMONG PEOPLE LIVING WITH HYPERTENSION IN SELECTED PUBLIC HOSPITALS IN ILORIN, NIGERIA
Mar 18, 2026, 21:38 PM -
A PILOT ASSESSMENT OF LLM-GENERATED SYNTHETIC COHORTS: A FIRST STEP TOWARD ROBUST SYNTHETIC CONTROL ARMS
Mar 18, 2026, 21:38 PM -
REAL-WORLD UTILIZATION SHIFTS AND AI/NLP-DERIVED CLINICAL DRIVERS OF BIOLOGIC-TO-BIOSIMILAR SWITCHING IN INFLAMMATORY BOWEL DISEASE (IBD)
Mar 18, 2026, 21:38 PM -
PATIENT CHARACTERISTICS AND UTILIZATION OF ADALIMUMAB-BWWD IN THE US DEPARTMENT OF VETERANS AFFAIRS POPULATION
Mar 18, 2026, 21:38 PM -
RACIAL AND ETHNIC DISPARITIES IN POST-SURGICAL PAIN MANAGEMENT AMONG PATIENTS UNDERGOING ORTHOPEDIC SURGERY IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
INCORPORATING DYNAMIC DRUG PRICING IN US COST-EFFECTIVENESS MODELS: A HYPOTHETICAL SIMULATION STUDY
Mar 18, 2026, 21:38 PM -
REAL-WORLD ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING BETWEEN BIOLOGICS AND BIOSIMILARS IN IMMUNE-MEDIATED INFLAMMATORY DISEASES
Mar 18, 2026, 21:38 PM -
METHODOLOGICAL DIVERGENCE AND POLICY IMPACT OF HTAS FOR IMMUNE CHECKPOINT INHIBITORS IN NSCLC
Mar 18, 2026, 21:38 PM -
MARKOV MODEL-BASED COST-UTILITY ANALYSIS COMPARING RANIBIZUMAB WITH PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY IN INDIA
Mar 18, 2026, 21:38 PM -
COST EFFECTIVENESS OF EARLY VS DELAYED AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Mar 18, 2026, 21:38 PM
